Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy …
Background Prolonged myelosuppression following CD19-directed CAR T-cell transfusion
represents an important, yet underreported, adverse event. The resulting neutropenia and …
represents an important, yet underreported, adverse event. The resulting neutropenia and …
Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy
GM Maron, DR Hijano, R Epperly, Y Su, L Tang… - Frontiers in …, 2022 - frontiersin.org
CD19-specific chimeric antigen receptor (CAR) T cell therapy has changed the treatment
paradigm for pediatric, adolescent and young adult (AYA) patients with relapsed/refractory B …
paradigm for pediatric, adolescent and young adult (AYA) patients with relapsed/refractory B …
Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy
Y Liu, X Chen, D Wang, H Li, J Huang… - Journal of …, 2018 - journals.lww.com
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen
receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and …
receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and …
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
K Rejeski, A Perez, G Iacoboni, V Blumenberg… - Science …, 2023 - science.org
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
[HTML][HTML] Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells
CTLO19 cells are CAR-modified T cells which recognize CD19 and produce high durable
remission rates for pts with relapsed or refractory acute lymphoblastic leukemia (ALL) …
remission rates for pts with relapsed or refractory acute lymphoblastic leukemia (ALL) …
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
JA Hill, D Li, KA Hay, ML Green… - Blood, The Journal …, 2018 - ashpublications.org
Lymphodepletion chemotherapy with CD19-targeted chimeric antigen receptor–modified T
(CAR-T)-cell immunotherapy is a novel treatment for refractory or relapsed B-cell …
(CAR-T)-cell immunotherapy is a novel treatment for refractory or relapsed B-cell …
Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant
P Liu, M Liu, C Lyu, W Lu, R Cui, J Wang, Q Li… - Frontiers in …, 2020 - frontiersin.org
We studied the acute graft-versus-host disease (GVHD) after humanized anti-CD19-CAR T
therapy in relapsed B-acute lymphoblastic leukemia (ALL) patients after allogeneic …
therapy in relapsed B-acute lymphoblastic leukemia (ALL) patients after allogeneic …
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a …
KPL Cheok, A Farrow, D Springell… - The Lancet Infectious …, 2024 - thelancet.com
Chimeric antigen receptor (CAR) T-cell therapy leads to durable remissions in relapsed B-
cell cancers, but treatment-associated immunocompromise leads to a substantial morbidity …
cell cancers, but treatment-associated immunocompromise leads to a substantial morbidity …
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, MA Perales - Bone marrow transplantation, 2022 - nature.com
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …
providing excellent remission rates and durable disease control for patients with …
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
N Gagelmann, GG Wulf, J Duell, B Glass… - Blood …, 2023 - ashpublications.org
Hematotoxicity after chimeric antigen receptor (CAR) T-cell therapy is associated with
infection and death but management remains unclear. We report results of 31 patients …
infection and death but management remains unclear. We report results of 31 patients …